• Advise client on legislative and administrative policy-making related to the biopharmaceutical industry generally, and client priorities specifically. Includes raising awareness amongst public officials about the importance of addressing disease areas of high unmet medical need where client and its affiliates are working to develop new medicines.

Duration: February 6, 2017 to June 30, 2017

General Issues: Health Issues

Spending: about $130,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2017: U.S. Senate, House of Representatives

Related Foreign Entities: Roivant Sciences Ltd. (Hamilton, BER); contribution to lobbying: $0; ownership 100%; Roivant Sciences Holdings Ltd. (London, GBR); contribution to lobbying: $0; ownership 100%; Roivant Sciences GmbH (Basel, SUI); contribution to lobbying: $0; ownership 0%; Axovant Sciences Ltd. (Hamilton, BER); contribution to lobbying: $0; ownership 0%; Axovant Sciences GmbH (Basel, SUI); contribution to lobbying: $0; ownership 0%